Key Players
Competitive Landscape
Four supplier types compete in the soft tissue sarcoma market: diversified oncology groups with marketed systemic therapies, rare-tumor specialists with subtype programs, engineered cell-therapy operators and clinical-stage biotechs developing antibody-drug conjugates or immunotherapies. Their models differ because hospital infusions, oral targeted products and patient-specific cell therapies require different testing, distribution and service networks.
Capital and program ownership have moved in two directions since 2025: toward commercial cell-therapy consolidation and toward smaller biomarker or immune programs entering soft tissue sarcoma trials. US WorldMeds completed a $55 million asset purchase in July 2025. Adcendo dosed the first ADCE-D01 patient in June 2025. Treatment centers compare suppliers on indication fit, testing burden and delivery readiness.
Company developments mapped to drivers, trends and opportunities (2026-2036)
| Development | Driver | Trend | Opportunity |
|---|---|---|---|
| US WorldMeds completed the $55 million acquisition of TECELRA, lete-cel, afami-cel and uza-cel assets on July 31, 2025. | Sarcoma centers need uninterrupted access to an approved therapy and one accountable operator for patient support. | Commercial cell-therapy assets are consolidating under companies prepared to manage manufacturing and treatment-center logistics. | Revenue depends on expanding authorized-center coverage and converting biomarker-positive referrals into scheduled treatments. |
| Adcendo dosed the first ADCE-D01 patient in the Phase I/II ADCElerate1 trial on June 10, 2025. | Oncology teams need options for metastatic or unresectable disease following standard systemic treatment. | Antibody-drug conjugates are moving into soft tissue sarcoma-specific clinical testing across several subtypes. | A uPARAP-directed therapy could serve biomarker-defined trial populations and support specialist-center partnerships. |
| Immutep reported in May 2025 that EFTISARC-NEO met its Phase II primary endpoint and exceeded the prespecified 35% median response benchmark. | Surgical teams need neoadjuvant regimens that improve tumor response without delaying resection. | Immunotherapy is being tested with radiation before surgery instead of remaining limited to advanced disease. | Positive pathologic-response data can support larger studies and clinical partnerships with specialist sarcoma centers. |
Johnson & Johnson, Eisai Co., Ltd., Novartis AG and Bayer AG compete through established product access. No separate qualifying capital or trial milestone for these companies is mapped in the 2025-2026 table.
Source: Future Market Insights, Soft Tissue Sarcoma Market and Cell Therapy Manufacturing Market Reports, 2026-2036. Primary records include the USA SEC, USA FDA, Adcendo, Immutep, Moleculin and Lantern Pharma official sources.
US WorldMeds, Johnson & Johnson, Eisai Co., Ltd., Novartis AG, Bayer AG, Merck KGaA, PharmaMar S.A., Adcendo ApS, Immutep Limited, Moleculin Biotech, Inc. and Lantern Pharma Inc. collectively cover cytotoxic therapy, oral targeted treatment, cell therapy, antibody-drug conjugates, neoadjuvant immunotherapy and lung-metastasis research.
Who leads the Soft Tissue Sarcoma Market?
No single supplier leads every treatment route. Within this set, US WorldMeds holds the FDA-approved engineered T-cell therapy following its July 2025 asset acquisition. Johnson & Johnson, Eisai Co., Ltd., Novartis AG and PharmaMar S.A. retain established systemic or subtype-focused products.
Which suppliers have documented regulatory approvals or designations?
US WorldMeds holds the transferred TECELRA assets and rights for eligible synovial sarcoma patients. Adcendo ApS received Fast Track status for ADCE-D01 in October 2025, while Lantern Pharma Inc. received Orphan Drug Designation for LP-284 in January 2026.
Which companies provide biomarker-directed or subtype-focused products?
US WorldMeds provides MAGE-A4-directed TECELRA and is advancing NY-ESO-1-directed lete-cel. Eisai serves liposarcoma with eribulin, Bayer covers NTRK fusion-positive tumors and Adcendo is testing a uPARAP-directed antibody-drug conjugate across soft tissue sarcoma subtypes.
Which suppliers serve North America and Europe?
Adcendo is enrolling ADCE-D01 across United States and European sites. PharmaMar and Novartis maintain international systemic-therapy reach, while Immutep supports a Polish sarcoma-center program and US WorldMeds concentrates on United States commercial access.
Representative Company Overview
| Company | Positioning | Verified market-relevant capabilities |
|---|---|---|
| US WorldMeds | United States commercial | TECELRA for MAGE-A4-positive synovial sarcoma; cell-therapy assets acquired in July 2025 include lete-cel and related programs. |
| Johnson & Johnson | Global | Trabectedin for unresectable or metastatic liposarcoma or leiomyosarcoma following prior anthracycline treatment; hospital infusion delivery. |
| Eisai Co., Ltd. | Global | Eribulin for unresectable or metastatic liposarcoma following prior anthracycline therapy. |
| Novartis AG | Global | Pazopanib for advanced soft tissue sarcoma following prior chemotherapy; oral delivery. |
| Bayer AG | Global | Larotrectinib for NTRK fusion-positive solid tumors including eligible soft tissue sarcoma patients. |
| PharmaMar S.A. | Europe and international markets | Trabectedin franchise and lurbinectedin development in metastatic leiomyosarcoma. |
| Adcendo ApS | United States and European clinical sites | ADCE-D01 uPARAP-directed antibody-drug conjugate in Phase I/II clinical testing. |
| Immutep Limited | Australia and European clinical research | Efti with radiotherapy and pembrolizumab in neoadjuvant resectable soft tissue sarcoma; Phase II endpoint met in May 2025. |
| Moleculin Biotech, Inc. | United States clinical development | Annamycin program for soft tissue sarcoma lung metastases; Phase 1B/2 topline results reported in June 2025. |
| Lantern Pharma Inc. | United States clinical development | LP-284 received FDA Orphan Drug Designation for soft tissue sarcomas in January 2026; it is not a marketed therapy. |
| Merck KGaA | Global clinical development | M3554 anti-GD2 antibody-drug conjugate was listed in Phase I development for advanced solid tumors including soft tissue sarcoma in May 2026. |
Research Methodology
The companies here show how the soft tissue sarcoma market is structured and do not form a ranking. A company appears where current evidence confirms an approved therapy, an active clinical program or a market-relevant development. Evidence comes from regulator records, filings, official company releases and clinical-trial records. Registrations belong to the entity that holds them. The 34.0% chemotherapy figure is an FMI estimate for 2026.
